Vaccine Minnow Medigen Targets Taiwan’s Allies for Growth
- Medigen aims to expand production 10-fold to 100m doses
- Clinical trials and cost are likely hurdles to overseas growth
Workers on the Medigen Vaccine Biologics Corp. (MVC) COVID-19 vaccine packaging line, in Hsinchu, Taiwan.
Photographer: Billy H.C. Kwok/BloombergThis article is for subscribers only.
Taiwanese vaccine maker Medigen Vaccine Biologics Corp.’s shot has already been used by president Tsai Ing-wen over better-known, more established inoculations.
Now the company is aiming to sell 100 million doses next year by gaining clearance from three to five additional countries, President Charles Chen said in an interview. The ambitious target comes despite the fact that Medigen hasn’t yet started the final trials typically required for approval. About 660,000 doses have been given locally thus far based on early study results.